CEO, President & Board Director
Rekha Hemrajani, M.B.A. joined Aravive as President and Chief Executive Officer in January 2020. She has more than 20 years of biopharmaceutical industry experience and has extensive expertise in all aspects of corporate strategy, corporate and business development, financing, and operations. Previously, Ms. Hemrajani served as chief operating officer and chief financial officer of Arcus Biosciences (NASD: RCUS), Inc. where she led corporate strategy, finance, investor relations, corporate communications, business and corporate development, strategic planning, and human resources. Previously, she was chief operating officer for FLX Bio (now RAPT Therapeutics NASD: RAPT), chief financial officer and senior vice president of business and financial operations at 3-V Biosciences (now Sagimet Biosciences), vice president, head of licensing and mergers and acquisitions at Onyx Pharmaceuticals, Inc. (NASD: ONXX), and vice president of business development at Exelixis, Inc (NASD:EXEL). Ms. Hemrajani began her career in investment banking at Credit Suisse and Lehman Brothers. Ms. Hemrajani earned a B.S. in Economics and Computer Science from the University of Michigan and an M.B.A. from the Kellogg Graduate School of Management at Northwestern University. Ms. Hemrajani is a member of the Board of Directors of Adverum Biotechnologies (NASD:ADVM), a clinical-stage gene therapy company.